LOS ANGELES--(BUSINESS WIRE)--
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Alexion investigation page on our website at www.glancylaw.com/case/alexion-pharmaceuticals-inc.
On May 8, 2017 Alexion’s Sao Paulo offices were raided as part of an investigation into the Company’s business practices. According to law enforcement officials, Alexion may be involved in a scheme wherein the Company, with the aid of a local patient association, subsidized lawsuits for patients to get access to the Company’s drug via Brazil’s national health system. On this news, shares of Alexion have fell over 4% on May 8, 2017.
On May 17, 2017, the Company’s CEO confirmed the Sao Paulo raid on Alexion’s offices and informed investors that the Company is reviewing its spending and compliance practices. On this news, shares of Alexion fell $4.15 per share, or over 3%, to close on May 17, 2017 at $116.15 per share.
If you purchased Alexion securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.